Table of Content
Introduction
Executive Summary
Gastrointestinal Stromal Tumors: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Gastrointestinal Stromal Tumors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Gastrointestinal Stromal Tumors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Famitinib: Jiangsu Hengrui Medicine
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
DS 6157: Daiichi Sankyo Company
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
• Comparative Analysis
Gastrointestinal Stromal Tumors Key Companies
Gastrointestinal Stromal Tumors Key Products
Gastrointestinal Stromal Tumors- Unmet Needs
Gastrointestinal Stromal Tumors- Market Drivers and Barriers
Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
Gastrointestinal Stromal Tumors Analyst Views
Gastrointestinal Stromal Tumors Key Companies
Appendix
List of Figures
Figure 1 Total Products for Gastrointestinal Stromal Tumors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
List of Tables
Table 1 Total Products for Gastrointestinal Stromal Tumors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products